BR112016017444A2 - molécula e método - Google Patents

molécula e método

Info

Publication number
BR112016017444A2
BR112016017444A2 BR112016017444A BR112016017444A BR112016017444A2 BR 112016017444 A2 BR112016017444 A2 BR 112016017444A2 BR 112016017444 A BR112016017444 A BR 112016017444A BR 112016017444 A BR112016017444 A BR 112016017444A BR 112016017444 A2 BR112016017444 A2 BR 112016017444A2
Authority
BR
Brazil
Prior art keywords
alms1
apkc
relates
present
diabetes
Prior art date
Application number
BR112016017444A
Other languages
English (en)
Inventor
Petrovsky Nikolai
Marion Vincent
Original Assignee
Inst Nat Sante Rech Med
Univ Strasbourg
Vaxine Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Univ Strasbourg, Vaxine Pty Ltd filed Critical Inst Nat Sante Rech Med
Publication of BR112016017444A2 publication Critical patent/BR112016017444A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)

Abstract

a presente invenção se refere à identificação da alms1 como a peça chave ausente envolvida na regulação da absorção de glicose mediada por insulina através de vesículas de seleção de glut4 e à infrarregulação da alms1 por apkc. por conseguinte, a presente invenção se refere a uma molécula capaz de evitar a ligação da apkc à alms1, para uso no tratamento ou prevenção do diabetes, em particular o diabetes tipo 2. além disso, a presente invenção se refere a um método para a identificação de moléculas capazes de evitar a ligação da apkc à alms1.
BR112016017444A 2014-01-29 2015-01-29 molécula e método BR112016017444A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14153017 2014-01-29
PCT/EP2015/051856 WO2015114062A1 (en) 2014-01-29 2015-01-29 New target for diabetes treatment and prevention

Publications (1)

Publication Number Publication Date
BR112016017444A2 true BR112016017444A2 (pt) 2017-10-10

Family

ID=50000917

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016017444A BR112016017444A2 (pt) 2014-01-29 2015-01-29 molécula e método

Country Status (8)

Country Link
US (2) US10821159B2 (pt)
EP (2) EP3501531A1 (pt)
CN (1) CN106456700B (pt)
BR (1) BR112016017444A2 (pt)
CA (1) CA2937447A1 (pt)
EA (1) EA201691498A1 (pt)
ES (1) ES2714355T3 (pt)
WO (1) WO2015114062A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016017444A2 (pt) 2014-01-29 2017-10-10 Inst Nat Sante Rech Med molécula e método
EP3421485A1 (en) * 2017-06-30 2019-01-02 Université de Strasbourg Peptides for treatment and prevention of hyperglycaemia
LT3723782T (lt) 2017-12-14 2026-02-10 Université De Strasbourg Peptidai, skirti nealkoholinės kepenų suriebėjimo ligos gydymui ir profilaktikai
RS64265B1 (sr) * 2018-12-21 2023-07-31 Univ Strasbourg Peptidi za lečenje i prevenciju dijabetesa i povezanih poremećaja
CN112904014B (zh) * 2019-12-04 2023-01-13 张曼 尿液TBC1D5a蛋白及其多肽片段在正常妊娠或妊娠糖尿病中的应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ES2188985T3 (es) 1996-08-30 2003-07-01 Jens Peter Furste Seleccion enantiomerica y evolucion enantiomerica de acidos nucleicos.
US6225120B1 (en) * 1997-05-15 2001-05-01 The General Hospital Corporation Therapeutic and diagnostic tools for impaired glucose tolerance conditions
US6833436B2 (en) * 1997-05-21 2004-12-21 Children's Medical Center Corporation Short peptides which selectively modulate the activity of serine/threonine kinases
WO2000018895A1 (en) * 1998-09-25 2000-04-06 The Children's Medical Center Corporation Short peptides which selectively modulate the activity of protein kinases
JP2003516760A (ja) * 1999-12-02 2003-05-20 ユニヴァーシティー オブ ダンディー プロテインキナーゼ調節
US7029892B1 (en) * 2000-07-19 2006-04-18 Amgen, Inc. Serine threonine kinase member, h2520-59
US20020162127A1 (en) * 2001-01-30 2002-10-31 Yizhong Gu Human protein kinase domain-containing protein
AU2002330649A1 (en) * 2001-10-15 2003-04-28 University Of Southampton Diagnosis and therapy of conditions involving alms1
DE10244453A1 (de) * 2002-09-24 2004-04-01 Phenomiques Gmbh Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
JP2007530000A (ja) * 2003-07-17 2007-11-01 ユニヴァーシティー オブ ダンディー Ｌｋｂ１／ｓｔｒａｄ７ｍ０２５複合体の使用方法
WO2005079300A2 (en) * 2004-02-13 2005-09-01 Albert Einstein College Of Medicine Of Yeshiva University Protein kinase inhibitors and methods for identifying same
US7265092B2 (en) * 2004-09-30 2007-09-04 Kai Pharmaceuticals, Inc. Pharmaceutical formulation
AU2006263332B2 (en) * 2005-06-29 2012-02-23 Hadasit Medical Research Services & Development Ltd. Protein kinase C inhibitors for prevention of insulin resistance and type 2 diabetes
AU2007257650A1 (en) * 2006-06-15 2007-12-21 Boehringer Ingelheim International Gmbh 2-anilino-4-(heterocyclic)amino-pyrimidines as inhibitors of protein kinase C-alpha
US20090081786A1 (en) * 2006-06-30 2009-03-26 Viktoria Kheifets Peptide sequences for modulation of protein kinase C
KR20100040912A (ko) * 2007-07-30 2010-04-21 힐로 리미티드 약제학적 조성물 및 관련 방법
EP2356139A4 (en) 2008-07-23 2013-01-09 Harvard College LIGURE COMBINED POLYPEPTIDES
US8586707B2 (en) 2008-09-16 2013-11-19 The Research Foundation Of State University Of New York Stapled peptides and method of synthesis
WO2011057063A2 (en) * 2009-11-06 2011-05-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for quantitatively monitoring lipids
GB201103631D0 (en) 2011-03-03 2011-04-13 Univ Leeds Identification of candidate therapeutics
US8580769B2 (en) * 2011-03-10 2013-11-12 The United States Of America As Represented By The Department Of Veterans Affairs Treatment of obesity, metabolic syndrome, and diabetes with protein kinase C inhibitors
US9260484B2 (en) 2011-06-15 2016-02-16 Ohio State Innovation Foundation Small molecule composite surfaces as inhibitors of protein-protein interactions
US9321763B2 (en) * 2012-04-04 2016-04-26 Rigel Pharmaceuticals, Inc. Protein kinase C inhibitors and uses thereof
BR112016017444A2 (pt) 2014-01-29 2017-10-10 Inst Nat Sante Rech Med molécula e método
EP3421485A1 (en) 2017-06-30 2019-01-02 Université de Strasbourg Peptides for treatment and prevention of hyperglycaemia
EP3437651A1 (en) 2017-08-03 2019-02-06 Université de Strasbourg Peptides for treatment and prevention of nonalcoholic fatty liver disease
LT3723782T (lt) 2017-12-14 2026-02-10 Université De Strasbourg Peptidai, skirti nealkoholinės kepenų suriebėjimo ligos gydymui ir profilaktikai

Also Published As

Publication number Publication date
US11826403B2 (en) 2023-11-28
US20210069301A1 (en) 2021-03-11
WO2015114062A1 (en) 2015-08-06
CA2937447A1 (en) 2015-08-06
CN106456700A (zh) 2017-02-22
CN106456700B (zh) 2020-02-18
US10821159B2 (en) 2020-11-03
US20170000857A1 (en) 2017-01-05
ES2714355T3 (es) 2019-05-28
EP3099312B1 (en) 2018-12-05
EA201691498A1 (ru) 2017-02-28
EP3099312A1 (en) 2016-12-07
EP3501531A1 (en) 2019-06-26

Similar Documents

Publication Publication Date Title
BR112015027055A8 (pt) bi-heteroarilas, usos das mesmas, e composição farmacêutica
CO2017003487A2 (es) Composiciones que comprenden polipéptidos gdf15 modificados para trastornos metabólicos
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
BR112015023001A2 (pt) composição de salto de exon para tratamento de distrofia muscular
BR112015022998A2 (pt) composições melhoradas para o tratamento de distrofia muscular
CO2017009433A2 (es) Proteínas específicas para pioverdina y pioquelina
CL2015003199A1 (es) Peptidos terapeuticos
BR112016014020A2 (pt) Compostos moduladores de tetra-hidropiridopirazinas de gpr6, seus sais e os usos dos mesmos
MX2017009044A (es) Metodo para el tratamiento de malignidades.
DOP2017000049A (es) Compuestos tricíclicos que contienen nitrógeno para el tratamiento de la infección por neisseria gonorrhoeae
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
BR112017000714A2 (pt) indols funcionalizados e substituídos como agentes anti-câncer
BR112016018062A8 (pt) compostos terapêuticos, composição farmacêutica e usos
MX2016005446A (es) Intervenciones a base de angiopoyetina para tratar la malaria cerebral.
CL2014002661A1 (es) Compuestos derivados de tienopirimidina o sus sales, como inhibidores de la alk quinasa; su proceso de preparacion; composicion farmaceutica que los comprende, util para el tratamiento del cancer.
ECSP14014778A (es) Composiciones derivadas de la quitosana
BR112015017241A2 (pt) doadores de nitroxil com índice terapêutico melhorado
BR112016000565A2 (pt) polipeptídeo cíclico, derivado ou análogo do mesmo e seu uso modulador alostérico, composição farmacêutica, processo para produzir a mesma
BR112017011226A2 (pt) peptídeo, composição farmacêutica, processo para fabricação da composição farmacêutica
MX2018006953A (es) Compuestos de platino funcionalizados con monomaleimida para la terapia del cancer.
BR112016029024A8 (pt) composto, composição farmacêutica e uso
BR112019011590A2 (pt) terapia genética para mucopolissacarídeos, tipo ii
BR112017014189A2 (pt) terapia de câncer com um parvovirus combinado com bevacizumabe
MX377995B (es) Moléculas de unión al receptor bag3 para uso como un medicamento.
BR112016016098A2 (pt) Compostos orgânicos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.